In this study, a high CD34% in autologous peripheral blood stem cell (PBSC) products from 71 AML patients was associated directly with a high relapse rate (P = 0.006) and inversely with disease-free survival (P = 0.003), irrespective whether patients were transplanted or not. The relapse rate at 12 months was 67% in a group with Ͼ0.8% CD34 + cells and 34% in a group with р0.8% CD34 + cells. Although the percentage of malignant CD34
Introduction
During the last two decades treatment outcome for acute myeloid leukemia (AML) patients younger than 60 years has improved substantially by the use of more intensive chemotherapy. About 80% of the patients achieve complete remission after treatment, although, unfortunately, only 40-50% of the patients are still in complete remission after 5 years. 1 Currently, in a large part of patients, treatment includes myelo-ablative chemotherapy followed by autologous stem cell transplantation. Minimal residual disease (MRD) cells in autologous bone marrow and/or in peripheral blood stem cell (PBSC) products might be at least in part responsible for relapses. In AML patients after induction chemotherapy, the percentage of MRD cells in bone marrow, and as a reflection in PBSC products, correlates with relapse rate and disease-free survival. [2] [3] [4] These studies were performed using combinations of cell surface markers present on leukemia cells, but not or in very low frequencies on normal cells, which allows MRD detection in up to 80% of the patients. [5] [6] [7] In studying the contamination of MRD cells in PBSC products with these leukemia associated phenotypes (LAPs) using flow cytometry, we found that a high percentage of CD34-positive cells in PBSC products was associated with a high relapse rate. This obser- vation shed another light on the general view that high CD34-positive cell doses are, in terms of hematological recovery, beneficial for patients treated with high-dose chemotherapy followed by PBSC transplantation. [8] [9] [10] Transplantation at a low dose of 1-2 x 10 6 CD34 + cells/kg is feasible, but results in a relatively slow recovery of both platelets and neutrophils. At a higher dose of 2-5 x 10 6 CD34 + cells/kg both the recovery of platelets and neutrophils is improved, while a further increase of the CD34 dose to 5-8 x 10
6 CD34 cells/kg has been recommended for an even faster platelet recovery. 8 Notably, AML is a CD34-positive disease in contrast to other diseases treated with autologous transplantation regimens, such as lymphoma, multiple myeloma and breast cancer. A high relapse rate of patients having transplants with a high percentage of CD34-positive cells would be alarming, not only in terms of transplant contamination but also in terms of ineffective in vivo purging during the preceding chemotherapeutic treatment. The present study was undertaken firstly to verify our preliminary results in a larger group of patients and secondly to attempt to offer an explanation for this. The analysis resulted in possibly important clinical consequences.
Materials and methods

Treatment design and clinical characteristics
In our hospital, de novo AML patients younger than 60 years were treated according to the Dutch HOVON 29 protocol from 1994 until 2000. 11 On entry, patients were randomized between remission induction courses of chemotherapy with and without G-CSF during chemotherapy. The first cycle of chemotherapy consisted of cytarabine (200 mg/m 2 /day, days 1-7) and idarubicin (12 mg/m 2 /day, days 6-8) while the second cycle included cytarabine (1000 mg/m 2 /day, days 1-6) and amsacrine (120 mg/m 2 /day, days 4-6). In case of G-CSF administration, 150 g/m 2 /day lenograstim was given subcutaneously on day −1 until the last day of chemotherapy. After reaching complete remission and when the granulocyte count had risen to 0.5 x 10 9 /l after cycle 2, lenograstim (600 g/m 2 /day) was started in all patients in both arms for mobilization and collection of CD34 + cells by leukapheresis. PBSC products were processed and cryopreserved in autologous plasma containing 10% DMSO using controlled freezing rate with the Kryo10 (Cryotech, Benelux). In case of intermediate or high risk, a second randomization was performed for either a third cycle of chemotherapy consisting of mitoxantrone (10 mg/m FAB classifications, except M3) included in this study are described in Table 1 .
Cytogenetics
Favorable cytogenetic aberrations included t(8,21)(q22;q22) and inv16 (p13q22); M3 patients (n = 6) with t(15,17)(q22;q21) were not included in this study. The presence of a complex karyotype (a clone with at least five unrelated abnormalities), monosomies of chromosome 5 or 7, deletions of the long arm of chromosome 5 or 3q abnormalities were designated as unfavorable aberrations. The remaining karyotypes, including the normal ones or those with structural or numerical changes not encompassed by the favorable and unfavorable groups were defined as intermediate aberrations. 12 
Leukemia-associated phenotypes (LAP) and CD34 expression on de novo AML
For immunophenotypical analysis of leukemia blasts with the aim to find a leukemia-associated phenotype (LAP), a doublestep procedure was used. First, a panel of 15 quadruple mono- Fourteen patients had not received a post-remission therapy due to an early relapse (n = 10), an extremely high toxicity during the second course of the remission induction therapy (n = 2) or early death (n = 2). 
Percentage of CD34-positive cells in PBSC products
The percentage of CD34 + cells in PBSC products was measured using anti CD34-PE (Becton Dickinson) and anti CD45-FITC (Coulter) and analyzed according to the ISHAGE method. 13 A minimum of 100 positive events for CD34 was acquired for reliable detection of the percentage CD34-positive cells. In this study CD34
+ cells were harvested in 1-5 leukapheresis sessions (median n = 1, mean n = 1.9). For the correlation of the yield of the CD34
+ cells with response parameters our choice was the leukapheresis session with the highest percentage of CD34 + cells, since the highest percentage is hardly dependent on variations between patients and adequacy of the onset of leukapheresis procedure, while the percentage of CD34 + cells, in contrast to CD34 + cells/kg body weight, is independent of the duration of flow speed and the leukapheresis procedure.
Detection and quantification of MRD frequencies in PBSC products
For MRD detection fresh and in some cases cryopreserved/thawed cells were incubated with appropriate MoAb combinations to be able to detect cells with expression of the LAP as defined previously in the corresponding de novo AML. Extensive validation of the use of cryopreserved material showed no selective loss of subgroups of cells. 6 About 0. + phenotype could be excluded in these cases by comparing de novo AML with relapsed AML in paired samples (n = 7).
Outcome measures
Remission was defined as complete if cellularity in bone marrow was more than 20% with evidence of normal erythropoiesis, granulopoiesis and megakaryopoiesis and with less than 5% blasts. In addition, granulocytes and platelets in peripheral blood should be at least 1.5 x 10 9 /l and 100 x 10 9 /l, respectively. 15 Relapse was defined as marrow infiltration by more than 5% blasts in previously normal bone marrow. Diseasefree survival was defined as the interval between the dates of complete remission and relapse and overall survival between the dates of registration and death. Patients still in remission were censored in statistical analyses at the time of last followup. The duration of pancytopenia with regard to white blood cells (Ͼ1 x 10 9 /l), polymorphonucleated cells (Ͼ0.5 x 10 9 /l or Ͼ1 x 10 9 /l) and platelets (Ͼ50 x 10 9 /l or Ͼ100 x 10 9 /l) was calculated from the day of the start of the cycle of chemotherapy until the day of recovery.
Statistical analysis
The analysis of the groups of patients with different percentages of CD34 + cells in PBSC products was tested with the chisquared likelihood method. For correlations of percentages of CD34 + cells in PBSC products with hypoplasia periods the log-rank test was used. The log rank test was also applied for the correlation between MRD% in PBSC products and disease-free survival. The Kaplan-Meier approach was used for disease-free and overall survival and significant differences between different groups were calculated using log-rank test. Multivariate analysis was performed with the Cox proportional hazard model.
Results
Percentage of CD34 + cells in PBSC products and clinical outcome
After remission induction chemotherapy CD34
+ cells were harvested in 1-5 sessions. The PBSC product with the highest Figure 1 Disease-free survival of AML patients as a function of the CD34% in PBSC products. The graph shows the disease-free survival (DFS) of the poor risk (CD34% Ͼ0.8) and good risk (CD34% Յ0.8) patients. The median DFS was 6 months for the first group and 16 months for the latter group (P = 0.003).
percentage of CD34
+ cells (see Materials and methods) was correlated with the disease-free survival (DFS). A high percentage of CD34
+ cells in PBSC products significantly correlated with a short DFS: at a cut-off level of 0.8% CD34 + cells, which is the median percentage of all products, the DFS was significantly lower (P = 0.003) in the group of patients with Ͼ0.8% CD34 + cells compared with patients with Յ0.8% CD34 + cells at a minimum follow-up of 12 months (Figure 1 ). Differences in overall survival were borderline significant (P = 0.07). The relapse rate (RR), at a median DFS of 12 months, was significantly (P = 0.006) higher in the group of patients with more than 0.8% of CD34
+ cells compared with the group with less than 0.8% CD34 + cells (69% vs 34%, Table 2 ). This conclusion was independent of the choice of the cut-off levels for the percentage of CD34 + cells and DFS: at a minimum followup of either 12 or 18 or 24 months, DFS in each of these cases correlated significantly with cut-off levels of both 0.6% and 0.8% and 1.2% CD34 + cells (data not shown). Furthermore, not only the percentage of CD34 + cells, but also the total number of CD34
+ cells/kg of PBSC products with the highest yield correlated with relapse rate: differences were significant (P Յ 0.05) at a cut-off level of 10 x 10 6 CD34 + cells/kg at 12 
Multivariate analysis
An important aspect in this study is that half of the patients did not receive their PBSC products since they were randomised for standard-dose chemotherapy and not for high-dose chemotherapy followed by PBSC transplantation. However, multivariate analysis showed that this did not play a role in the relation between CD34% in PBSC and relapses ( Table 3 ). The same was true for G-CSF administration during the remission induction therapy. Also, the prognostic factors white blood cell (WBC) count at presentation of disease and age were studied in multivariate analyses. The percentage of patients with good and adverse risk cytogenetic aberrations were too low (6% and 4%, respectively) for performing statistical analysis. The WBC count and age were divided in subgroups since the numbers of patients were too low for use as continuous variables. By defining three groups: WBC Յ 20 x 10 9 /l, WBC Ͼ20 x 10 9 /l and Յ100 x 10 9 /l and WBC Ͼ100 x 10 9 /l ( Table 1 ) we found that the group of 12 patients with Ͼ100 x 10 9 WBC/l had a significantly (P = 0.05) higher RR at 12 months than the group of 39 patients with less than 20 x 10 9 WBC/l. Also, three groups of patients with different ages were defined: 18-30, 31-45 and 46-60 years ( Table 1) . Age of the patient, however, was not a prognostic factor in this study, not surprisingly since all patients were relatively young as a result of the inclusion criterion on age (Materials and methods). Multivariate analysis showed that the prognostic value of percentage of CD34 + cells in PBSC products was independent of WBC count and age (Table 3) .
Nature of CD34 + cells in PBSC products and its relation with disease-free survival
The contribution of malignant CD34 + cells to the total CD34 + population in PBSC products was determined in order to explain the poor prognostic value of the high percentage of CD34 + cells. The nature of these CD34 + cells could be measured by examining (1) if CD34 was expressed on de novo AML and if so (2) whether leukemia-associated phenotypes (LAPs) could be defined that include these CD34
+ cells. Figure  2 shows an example of both a CD34-negative AML (Figure  2a,b) and a CD34-positive AML having a CD34 + LAP (Figure Table 3 Effect of variables on the relation between CD34% in PBSC products and relapses
Groups compared
Relative risk P + compartment (Figure 3 ). This indicates that in the group with Ͼ0.8% CD34 the fraction of malignant CD34 + cells does not explain the high relapse rate. In the
Figure 2
Examples of CD34 and leukemia associated phenotype expression on material from de novo AML and PBSC products. Density plots (a) and (b) show an AML sample without CD34 expression (a) and isotype control (b). In plots (c) and (d) a de novo AML sample was stained for CD34, CD13 and CD7 expression. 
Figure 3
Relation between PBSC CD34% and the malignant fraction of the CD34 + compartment. The nature of CD34 + cells in PBSC products has been established by using the approach outlined under Material and methods 'Detection and quantification of MRD frequencies in PBSC products' in 49 samples. Note the absence of a direct relation between total CD34% and the malignant fraction herein.
group with DFS Յ12 months and CD34 Ͼ0.8%, for example, this fraction was median only 8%.
Frequency of total MRD cells and of normal CD34
+ cells in PBSC products. Relation with disease-free survival
Although a short disease-free survival in patients with Ͼ0.8% CD34 + cells in PBSC products was not due to the predominance of malignant CD34 + cells, it still might be (and in fact is) that the total number of malignant CD34 + cells in this group is higher than in the group with Յ0.8% CD34. Moreover, a CD34-negative AML, which does not contribute to the contamination of the CD34 + population in PBSC products, may contribute to total transplant MRD by virtue of its CD34-negative compartment. Following this, total MRD as a percentage of WBC in PBSC products has been measured in 36 evaluable cases and revealed a very significant inverse correlation (P Ͻ 0.001) with disease-free survival (Figure 4) . Interestingly, Figure 5a now reveals that the frequency of MRD cells was not strictly dependent on CD34% in PBSC products: MRD frequency of the patients with Ͼ0.8% CD34 + cells and relapsing within 12 months (median MRD%: 0.65%) was significantly (P = 0.05) higher than that of the group of patients with Ͼ0.8% CD34 + cells and disease-free survival longer than 12 months (median MRD%: 0.05%). The high MRD frequency was now predominantly present in the two groups relapsing within 12 months.
Similar to Figure 5a for MRD cells, Figure 5b shows the frequency of the corresponding normal CD34
+ cells as a percentage of WBC. The group of patients with Ͼ0.8% CD34 + cells and DFS Յ12 months was the only group with high frequencies of both normal and MRD cells. In this group of patients the data thus strongly suggest a reduced toxic effect of the preceding chemotherapeutic regimens on both malignant and normal cells. Total MRD% in PBSC products in relation to disease-free survival. Significant correlation (P Ͻ 0.001) between the percentage of total MRD cells in PBSC products and disease-free survival in 36 patients. The circles represent the patients who had relapsed and the triangles the patients who were still in remission at the moment of evaluation. The presence of these remission patients only in the left part (low MRD frequencies) of the figure indicates that the final correlation most probably will be even better.
Relation between hypoplasia duration after chemotherapy and CD34% in PBSC products
The putative low toxicity of the remission induction chemotherapy on normal cells was tested by determining the duration of hypoplasia following the second cycle of chemotherapy that preceded the mobilization of CD34 + cells. The hypoplasia period inversely correlated significantly (P Յ 0.002) with CD34% in PBSC products for both platelets (Ͼ50 x 10 9 /l and Ͼ100 x 10 9 /l) and PMN (Ͼ0.5 x 10 9 /l and Ͼ1.0 x 10 9 /l) ( Figure 6 ). Toxicity to normal hematopoiesis seems patient related, since the hypoplasia period after the second cycle correlated significantly (P Ͻ 0.05) with that after the first cycle both for at least WBC and platelets Ͼ50 x 10 9 /l and platelets Ͼ100 x 10 9 /l (data not shown).
Discussion
The present study shows that a high content of CD34 + stem cells, in autologous peripheral blood stem cell (PBSC) products of AML patients is an adverse prognostic factor. Calculation of both malignant contamination and normal CD34 + progenitor content revealed that this was mainly caused by the presence of a subgroup of early relapsing patients. We hypothesize that in this group the remission induction therapy has resulted in both an insufficient in vivo purging and a low toxicity towards the normal bone marrow progenitor cells. In detail this was based on the findings that this group of patients showed (1) the highest MRD%, (2) the highest normal CD34%, and (3) the shortest hypoplasia period preceding stem cell mobilization. So far, the relation between CD34 content in PBSC products and clinical outcome in AML has been reported in another large study, 16 but no MRD data were available in that study, which as we have shown in the present investigation, are indispensable for the explanation of these unexpected results. In our study it is interesting to note that the poor risk group of patients with the high CD34% (median: 1.7%) had a median cell dose of 5.9 x 10 6 CD34 + cells/kg and
Figure 5
Total MRD and normal CD34 as a percentage of WBC in PBSC products in relation to disease-free survival. (a) MRD% in PBSC products in the four different groups characterized by the disease-free survival (DFS) and CD34%. The median percentages are from left to right: 0.65%, 0.55%, 0.05% and 0.02%. In the group of patients with Ͼ0.8% CD34 + cells and with a DFS Ͼ12 months (the third group) three out of four patients were still in remission at the moment of evaluation and one patient had a relapse at 12.7 months. This patient showed the highest MRD% in this group. In the group (n = 4) with Յ0.8% CD34 + cells and DFS Ͼ12 months (the fourth group) two patients relapsed at 16 and 25 months and these also showed the highest MRD% in this small group of patients. (b) Normal CD34% in PBSC products in the four different groups characterized by the disease-free survival and CD34%. The normal CD34% could be established by correcting the total CD34% in PBSC products for the presence of malignant CD34
+ cells as determined in Figure 3 . The median percentages of normal CD34 + cells are from left to right: 2.05%, 0.27%, 1.46% and 0.37%. Note the high percentage of normal CD34
+ cells in the first poor risk group, which also had a high malignant contamination (see a).
thereby would qualify for a favorable group in terms of hematological recovery after transplantation. 8 In contrast, the median cell dose for the good risk CD34 group (median percentage 0.3%) was only 1.1 x 10 6 /kg, which in terms of hematological recovery is very low. Although hematological recovLeukemia ery after stem cell transplantation as well as the putative contribution to relapse of malignant cells present in the transplant are not main issues in the present paper, it may already be concluded that collection of high numbers of progenitor cells should thus not always be the ultimate goal to be achieved in autologous transplantation.
In this study, mainly due to absence of sufficient MRD data for bone marrow, we have assumed that the characteristics of the PBSC products studied largely reflect the corresponding bone marrow characteristics. This approach has been validated in another study in which MRD frequencies in bone marrow were shown to correlate significantly with MRD frequencies in PBSC products. 4 This is of importance since we have related transplant characteristics and disease-free survival in patients who all had stem cells collected according to study protocol, but were actually transplanted only in about half of the cases. In addition, the very strong correlation between MRD frequency in the PBSC product and clinical outcome, which has been reported in this paper and also in another study, 4 together with similar findings for MRD frequencies in bone marrow 2, 3 further validates this approach and supports the conclusions.
When subdividing the patients in four subgroups characterized both by CD34% (cut-off 0.8%) and by disease-free survival (cut-off 12 months), MRD frequency determinations turned out to offer the most conclusive explanation for the percentages of patients in remission at 12 months in these four defined groups ( Figure 5 ). The more detailed findings in these subgroups are also supported by both clinical and laboratory findings: patients with low MRD frequencies apparently have been treated relatively adequately in terms of leukemia cell kill, probably related to cellular sensitivity. In these patients normal CD34
+ cells, which have relatively high intrinsic drug resistance, 17 may be present either in high or low percentages depending on the actual chemotherapeutical concentrations reached in the bone marrow. In the patients with high MRD frequencies either low or high frequencies of normal CD34 + cells can be present: these patients have apparently been treated inadequately in terms of leukemia cell kill, probably related to cellular drug resistance and/or to the actual chemotherapeutical concentrations reached. Depending on these factors, the normal CD34 + cells might be differentially affected. In these cases a detailed analysis of drug resistance patterns would be relevant since in a preliminary study P-glycoprotein activity in de novo AML, which has been shown in many studies to be a poor prognostic factor, 18, 19 correlated with MRD as measured after remission induction chemotherapy in remission bone marrow. 20 Other cellular mechanisms that might contribute to leukemia resistance and poor outcome and which might be incorporated in such analyses include expression of anti-apoptotic proteins 21, 22 or high 5′nucleotidase activities. 23 Pertinent to our observation are the reliability of both detection and quantification of MRD. We have taken this into account firstly by carefully establishing that the CD34 negative AML samples (defined as Ͻ1% CD34 + ) used to define transplant CD34 + cells as normal, remained CD34-negative at relapse. Secondly, the consequent application of more than one leukemia-associated phenotype prevents pitfalls in MRD detection and quantification that may result from phenotypic shifts: 24, 25 no such potential pitfalls were observed using 17 paired de novo/relapse couples studied in this way (not shown).
Inadequate chemotherapy in terms of effect on both normal and malignant cells might be caused by differences in pharm-
